Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

被引：15

作者：

Mahteme, H. ^{[2
]}

von Heideman, A. ^{[1
]}

Grundmark, B. ^{[3
]}

Tholander, B. ^{[4
]}

Pahlman, L. ^{[2
]}

Glimelius, B. ^{[1
,4
]}

Larsson, R. ^{[3
]}

Graf, W. ^{[2
]}

Nygren, P. ^{[1
]}

机构：

[1] Uppsala Univ, Univ Hosp, Dept Oncol Radiol & Clin Immunol, S-75185 Uppsala, Sweden

[2] Uppsala Univ, Univ Hosp, Dept Surg Sci, S-75185 Uppsala, Sweden

[3] Uppsala Univ, Univ Hosp, Dept Med Sci, S-75185 Uppsala, Sweden

[4] Karolinska Inst, Radiumhemmet, Dept Pathol & Oncol, S-17176 Stockholm, Sweden

来源：

EJSO | 2008年 / 34卷 / 05期

关键词：

peritoneal carcinomatosis; intraperitoneal chemotherapy; cytotoxic drug; in vitro;

D O I：

10.1016/j.ejso.2007.05.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Aims: To investigate if the pattern of cytotoxic drug sensitivity in vitro in patient samples of peritoneal carcinomatosis (PC) is supportive to the current standardized approach for drug selection for perioperative intraperitoneal chemotherapy (IPC). Methods: The cytotoxic effect of cisplatin, oxaliplatin, irinotecan, 5-fluorouracil, mitomycin-C, doxorubicin and melphalan was investigated in vitro on tumour cells from 223 patient tumour samples of different PC origins. Results: Considerable differences in cytotoxic drug sensitivity between tumour types of the PC entity and within each tumour type were observed. Cisplatin showed high cross-resistance with oxaliplatin but low cross-resistance with doxorubicin and irinotecan. No cross-resistance was found between irinotecan and doxorubicin. The dose-response relationships for melphalan and irinotecan in individual samples showed great variability. Conclusions: The activity in vitro of cytotoxic drugs commonly used in IPC for PC is very heterogeneous. Efforts for individualizing drug selection for PC patients undergoing IPC seem justified. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：547 / 552

页数：6

共 20 条

[1]

Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[2]

Csoka K, 1997, INT J CANCER, V72, P1008

[3]

Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies [J].

Elias, D. ;

Raynard, B. ;

Bonnay, M. ;

Pocard, M. .

EJSO, 2006, 32 (06) :607-613

[4]

Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance [J].

Elias, D ;

Matsuhisa, T ;

Sideris, L ;

Liberale, G ;

Drouard-Troalen, L ;

Raynard, B ;

Pocard, M ;

Puizillou, JM ;

Billard, V ;

Bourget, P ;

Ducreux, M .

ANNALS OF ONCOLOGY, 2004, 15 (10) :1558-1565

[5]

RELATIONSHIP BETWEEN PHARMACOKINETIC PARAMETERS IN PATIENTS AND CYTOTOXICITY IN-VITRO OF STANDARD AND INVESTIGATIONAL ANTICANCER DRUGS [J].

FRIDBORG, H ;

NYGREN, P ;

LARSSON, R .

ANTI-CANCER DRUGS, 1995, 6 (01) :64-69

[6]

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia [J].

Glehen, O ;

Mohamed, F ;

Gilly, FN .

LANCET ONCOLOGY, 2004, 5 (04) :219-228

[7]

Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy [J].

Gomez Portilla, A. ;

Barrios, R. ;

Rutian, S. ;

Camps, B. ;

Bretcha, P. ;

Gonzalez Bayon, L. ;

Torres Melero, J. ;

Garcia Polavieja, M. ;

Gonzalez Moreno, S. .

EJSO, 2006, 32 (06) :628-631

[8]

Peritoneal surface oncology:: a progress report [J].

Gonzalez-Moreno, Santiago .

EJSO, 2006, 32 (06) :593-596

[9]

Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei [J].

Güner, Z ;

Schmidt, U ;

Dahlke, MH ;

Schlitt, HJ ;

Klempnauer, J ;

Piso, P .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2005, 20 (02) :155-160

[10]

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer [J].

Jaaback, K ;

Johnson, N .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)

← 1 2 →